GA
Therapeutic Areas
EyePoint Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| DURAVYU™ (EYP-1901) | Wet Age-Related Macular Degeneration (Wet AMD) | Phase 3 |
| EYP-2301 | Serious Retinal Diseases | Pre-clinical |
Leadership Team at EyePoint Pharmaceuticals
JS
Jay S. Duker, M.D.
President & CEO and Board Director
GO
George O. Elston
Executive Vice President, Chief Financial Officer
RR
Ramiro Ribeiro, M.D., Ph.D.
Chief Medical Officer
RH
Ron Honig, Esq.
Chief Legal Officer & Company Secretary
MC
Michael Campbell
Chief Commercial Officer
IL
Isabelle Lefebvre
Chief Regulatory Officer
JL
Jennifer Leonard
Chief People Officer and SVP, IT
MJ
Michael J. Maciocio
Chief Manufacturing Officer
MS
Marcia Sellos-Moura, Ph.D.
Chief Scientific Officer
NL
Nancy Lurker
Vice-Chair, Board of Directors